Compare KVYO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KVYO | ACAD |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.3B |
| IPO Year | 2023 | 2000 |
| Metric | KVYO | ACAD |
|---|---|---|
| Price | $17.85 | $25.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 22 |
| Target Price | ★ $34.48 | $30.55 |
| AVG Volume (30 Days) | ★ 3.4M | 1.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.29 | ★ 69.12 |
| EPS | ★ 0.03 | 0.02 |
| Revenue | ★ $1,234,019,000.00 | $726,437,000.00 |
| Revenue This Year | $24.47 | $18.80 |
| Revenue Next Year | $19.66 | $11.70 |
| P/E Ratio | ★ $611.67 | $1,327.00 |
| Revenue Growth | 31.63 | ★ 40.45 |
| 52 Week Low | $12.53 | $19.69 |
| 52 Week High | $36.76 | $28.35 |
| Indicator | KVYO | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 54.10 |
| Support Level | $17.48 | $25.00 |
| Resistance Level | $18.54 | $27.79 |
| Average True Range (ATR) | 1.09 | 0.75 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 63.39 | 52.73 |
Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.